Hutchison China Meditech Ltd (HCM)

 

Latest News

Chi-Med starts clinical trial in China

Hutchison China MediTech has initiated a phase I/II clinical trial of HMPL453 in China. Chi-Med said HMPL453 was a nov...

Chi-Med starts Ph I/II Trial of HMPL 453 in China

RNS Number: 8432I Hutchison China Meditech Limited 22 June 2017 Press Release ChiMed Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL453 in China London: Thursday , June 22, 2017: Hutchison China MediTech Limited ("ChiMed") (AIM/Nasdaq: HCM) has just initiated a Phase I/II clinical trial of HMPL453 in China. HMPL453 is a novel, highly...

Director's Share Dealing

RNS Number: 3179I Hutchison China Meditech Limited 16 June 2017 Director's Share Dealing London: Friday, June 16 , 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that:- 1. Dynamic Drive Limited, a person closely associated ("PCA") with Mr Simon To, Executive Director and Chairman, purchased a total of 11,1...

Fruquintinib NDA for Advanced CRC Filed with CFDA

RNS Number: 7715H Hutchison China Meditech Limited 12 June 2017 Chi-Med Submits New Drug Application to CFDA for Fruquintinib in Advanced Colorectal Cancer - Application accepted by CFDA for technical review by the Center for Drug Evaluation- - Triggers RMB30.8 million milestone payment from EliLilly and Company ("Lilly")- London: Monday, Ju...

All News

DateHeadlineSource
22-06-17Chi-Med starts clinical trial in China StockMarketWire
22-06-17Chi-Med starts Ph I/II Trial of HMPL 453 in ChinaRNS
16-06-17Director's Share DealingRNS
12-06-17Fruquintinib NDA for Advanced CRC Filed with CFDARNS
06-06-17Fruquintinib data highlighted at ASCO, says Chi-MedStockMarketWire
06-06-17Phase III Fruquintinib Data presented at ASCORNS
02-06-1712 AIM shares in the 1,000% clubInteractive Investor
18-05-17Broker Forecast - Panmure Gordon issues a broker note on Hutchison China Meditech LtdStockMarketWire
18-05-17Chi-Med Presents Clinical Data at ASCO 2017RNS
28-04-17Total Voting RightsRNS
27-04-17Results of Annual General MeetingRNS
13-04-17Why Shell was kicked out of this top-performing portfolioInteractive Investor
07-04-17Chi-Med present pre-clinical data at AACRStockMarketWire
07-04-17Pre-clinical Data Presented at AACRRNS
31-03-17Total Voting RightsRNS
29-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
29-03-17Vesting of LTIP awardsRNS
28-03-17Grant of Share Options under Share Option SchemeRNS
27-03-172016 Annual Report and Notice of AGMRNS
24-03-17Chi-Med chief scientific officer joins board StockMarketWire
24-03-17Appointment of DirectorRNS
21-03-17Chi-Med to host R&D BriefingsRNS
20-03-17Director Deals - Hutchison China Meditech Ltd (HCM)StockMarketWire
20-03-17Directors' Share DealingRNS
16-03-17Grant of Awards under Long Term Incentive PlanRNS
13-03-17Hutchison China MediTech shares tipped to hit record highInteractive Investor
13-03-17Higher commodity prices boost FTSE as May considers triggering Article 50StockMarketWire
13-03-17Record revenues and net income at Chi-Med StockMarketWire
13-03-17Publication of Form 20-FRNS
13-03-17Final ResultsRNS
10-03-17Chi-Med presents pre-clinical data at ENETSStockMarketWire
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
10-03-17Sulfatinib Phase Ib/II Results Presented at ENETSRNS
03-03-17Chi-Med reveals positive results from cancer drug trial StockMarketWire
03-03-17Positive Fruquintinib Pivotal Phase III ResultsRNS
28-02-17Board changes at HCMStockMarketWire
28-02-17Change of DirectorsRNS
20-02-17Chi-Med starts Savolitinib PSC trial in ChinaStockMarketWire
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS
20-02-17Start of Phase II Savolitinib PSC trial in ChinaRNS

RSS feeds

  • Editorial news feed for LSE:HCM Editorial
  • Regulatory news feed for LSE:HCM Regulatory